Kornimate/medical-research-clean huggingface dataset:
bone marrow suppression and recovery during radionuclide treatment

Conditions: Castration-resistant Prostate Cancer

Summary: radium-223-dichloride is approved therapy for patients with metastatic castration-resistant prostate cancer and bone metastases. more than 20 % of patients treated at rigshospitalet develop bone marrow suppression as a side effect to radium therapy the aim of the study is to examine biomarkers of bone marrow suppression and recovery during radium therapy as well as markers of bone remodeling.

radium-223-dichloride is approved therapy for patients with metastatic castration-resistant prostate cancer and bone metastases. therapy is administered intravenously every 4 weeks for up to 6 cycles. more than 20 % of patients treated at rigshospitalet develop bone marrow suppression as a side effect to radium therapy, which delays or excludes the patient from further oncological therapy. especially thrombocytopenia is a frequent side-effect and can be long lasting. the aim of the study is to examine whether biomarkers of bone marrow recovery (immature platelets, platelet volume, reticulocytes, red cell distribution width) can predict development of hematological toxicity during radium therapy. furthermore, to investigate whether these biomarkers can predict recovery from toxicity in patients who develop bone marrow suppression during therapy. a secondary aim of the study is to evaluate whether dynamics in biomarkers of bone remodeling during radium therapy is correlated to overall survival and time to symptomatic skeletal event. optimally these biomarkers can aid in monitoring therapy.

Eligibility criteria:
inclusion criteria: * metastatic castration resistant prostate cancer * planned to initiate radium therapy * age \> 18 years * able to understand study protocol and give informed consent exclusion criteria: * none
her2 pet imaging in breast cancer patients using [68ga]aby-025

Conditions: HER2-positive Breast Cancer

Summary: this is an open-labeled, exploratory, single center study. patients with a big primary breast cancer (≥ 3 cm) or metastatic first line, routinely have their her2-expression determined by biopsy. patients having a her2-positive tumor will be recruited to the study. a \[18f\]fdg pet/cect scan is performed for the measurement of uptake in the tumour and diagnosis of possible metastases. each subject will receive a single injection of the investigational product \[68ga\]aby-025, followed by measurement of uptake in the tumour or metastases and in normal organs. the investigations will be repeated after her2 directed therapy.

see above

Eligibility criteria:
inclusion criteria: 1. subject is \> 18 years of age 2. histologically or cytologically confirmed diagnosis of breast adenocarcinoma ≥ 3 cm determined by ultrasound, or locally advanced breast cancer (labc: t3-4nxmx or txn2-3mx) 3. her2-positiv breast cancer first recurrence 4. her2-positiv breast cancer primary metastatic 5. her2 status has been determined on biopsy material from the primary tumour and found to be her2-positive, defined as a dako herceptest™ score of 3+ or else 2+ and fish positive 6. \[18f\]fdg pet/cect performed within 7 days before administration of imp 7. ecog performance status of =\< 2 8. hematological, liver and renal function test results within the following limits: * white blood cell count: \> 2.0 x 10\^9/l * haemoglobin: \> 5.0 mmol/l * platelets: \> 50.0 x 10\^9/l * alt, alp: =\< 3 times upper limit of normal * bilirubin =\< 2.0 times upper limit of normal * serum creatinine: within normal limits 9. a negative pregnancy test (serum beta-hcg) at screening for all subjects of childbearing potential 10. subject is capable to undergo the diagnostic investigations to be performed in the study 11. informed consent exclusion criteria: * 1. known hypersensitivity to dotarem® 2. active known autoimmune disease or history of autoimmune disease 3. active serious infection according to investigator evaluation 4. known hiv positive or chronically active hepatitis b or c 5. administration of other investigational medicinal product within 30 days of screening 6. pregnant or breast-feeding 7. women capable of childbearing not using a sufficient non-hormonal method of birth control 8. other primary malignancies (including primary brain tumors) within the last 5 years before inclusion, with exception of sufficiently treated in situ carcinoma of the cervix, squamous carcinoma of the skin or sufficiently controlled limited basal cell carcinoma of the skin 9. signs of any other disease, metabolic or psychological dysfunction, findings at physical examination or laboratory findings, which give reasonable suspicion of a disease or condition that would contraindicate use of the imp, could influence the patient's compliance with the study routines or involves an increased risk for treatment-related complications.

Keywords: pet scan her2 breast cancer
bupivacaine liposome plus bupivacaine or ropivacaine for pericapsular nerve group block in hip arthroplasty (peng)

Conditions: Femoral Neck Fractures; Femur Head Necrosis; Hip Fractures

Summary: the goal of this clinical trial is to study the analgesic effect of liposomal bupivacaine plus bupivacaine for pericapsular nerve group (peng) block in postoperative pain management following hip replacement surgery. it will also assess the safety of liposomal bupivacaine for this purpose. the main questions it aims to answer are: 1. is liposomal bupivacaine plus bupivacaine superior to ropivacaine in terms of analgesic efficacy, duration of pain relief, opioid consumption, and patient satisfaction? 2. what medical problems do participants encounter when using liposomal bupivacaine plus bupivacaine for peng block in postoperative pain management following hip replacement surgery? researchers will compare liposomal bupivacaine plus bupivacaine to ropivacaine (a routinely used regional anesthetic in clinical practice) to determine if liposomal bupivacaine plus bupivacaine is more effective for pain management following hip replacement surgery. participants will: 1. receive liposomal bupivacaine plus bupivacaine or ropivacaine as a regional anesthetic for peng block under ultrasound guidance. 2. undergo hip replacement surgery under spinal anesthesia. 3. have pain relief, opioid analgesic consumption, and incidence of complications assessed at multiple time points within 72 hours after surgery.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists(asa) i\~ii * normal coagulation * clinical diagnosis of hip fracture exclusion criteria: * presence of severe systemic diseases or asa grade iii or higher * allergy to amide local anesthetics

Keywords: bupivacaine liposome peng block hip arthroplasty randomized controlled trial
dietary intervention with shop model - shopus

Conditions: Obesity

Summary: the objective is to investigate whether new nordic diet (nnd) versus average danish diet (add) in adults (18-65 y) with central obesity and components of the metabolic syndrome can improve body weight loss and risk markers of the metabolic syndrome, type 2 diabetes and cardiovascular diseases.


Eligibility criteria:
inclusion criteria: * abdominal obesity exclusion criteria: * bmi \> 45, previous weight change
role of hypertonic saline versus mannitol in the management of raised intracranial pressure in patients with alf

Conditions: Acute Liver Failure

Summary: patients with alf (acute liver failure) would undergo a detailed clinical evaluation. information would be collected regarding the onset and duration of symptoms, etiology, and severity of disease, other baseline clinical features, demographic characteristics, routine biochemical and hematological investigations. patients would also be screened for the assessment of raised intracranial hypertension by either clinical or neuroimaging or by onsd (optic nerve sheath diameter) and tcd (transcranial doppler ultrasonography). patient found to be having risen icp (intra cranial pressure) would be randomized in the two groups of the study. the group a would receive intravenous mannitol 20 to 30 minutes every 4 hourly where as those in the group b would be given 3% hypertonic saline as continuous infusion at a rate of 25ml /hr and titrated q4 hrs per sliding scale to achieve a target serum sodium level of 144-155 mmol/l .both the groups would receive other supportive measures such as head end elevation, oxygen supplementation, dextrose infusion to maintain normoglycemia standard medical treatment.


Eligibility criteria:
inclusion criteria: * patients with acute liver failure with age \>18 yrs * grade iii or grade iv he with raised icp * patient's next-of-kin consenting for the study protocol. exclusion criteria: * patients with ocular trauma. * k/c/o dcm, congestive heart failure, cerebral aneurysm, intracranial pathology * serum na\>160 and s creat\>1.5 mg% with oligurea
inverted t trabeculectomy primary congenital glaucoma

Conditions: Glaucoma, Congenital, Surgical Treatment

Summary: this study aims to evaluate the safety and efficacy of novel inverted t trabeculectomy in primary congenital glaucoma (pcg). it enrolled 50 eyes of 25 children with pcg. the mean age at the time of surgery was 12±11 months, and the mean presenting iop was 40±4 mmhg. patients with previous intra-ocular or conjunctival surgery, those who had significant ocular trauma, and patients with congenital glaucoma associated with ocular anomalies diseases were excluded from the study. all patients had inverted t trabeculectomy under general anesthesia. the iop in the operated eyes was followed up for 36 months.

this study included patients from the glaucoma clinic at benha university hospital between april 2015 and october 2017. all were diagnosed with pcg based on an intraocular pressure (iop) measurement of 21 mmhg or more at birth or shortly after, up to the age of 12 months. patients with previous intraocular or conjunctival surgery, those with significant ocular trauma, and those with congenital glaucoma associated with other ocular anomalies that would affect iop were excluded from the study. the procedure principles and potential complications were discussed with the children's parents or legal guardians, and they gave written informed consent before surgery. this study was approved by the benha faculty of medicine's ethical committee (approval number rc 9-1-2025) and conducted according to helsinki's declaration. all patients underwent complete ophthalmic examination under general anaesthesia before surgery. iop was measured 5 minutes after injecting intravenous ketamine 1mg/kg for induction of anaesthesia. we used a perkins tonometer (haag-streit, uk) to measure the iop before applying the eyelid speculum. corneal clarity was assessed under a surgical microscope, the corneal diameter was recorded using a surgical caliber, and fundus examination was done by indirect ophthalmoscope. a surgical swan jacob gonioprism assessed the anterior chamber angle when the cornea was clear enough to achieve a good view. all surgeries were performed under general anaesthesia by the same surgeon (aeh).

Eligibility criteria:
inclusion criteria: * pcg based on an intraocular pressure (iop) measurement of 21 mmhg or more at birth or shortly after, up to the age of 12 months exclusion criteria: * patients with previous intraocular or conjunctival surgery, those with significant ocular trauma, and those with congenital glaucoma associated with other ocular anomalies that would affect iop were excluded from the study
an open-label, phase ii trial of zd1839 (iressa) in patients with malignant mesothelioma

Conditions: Mesothelioma

Summary: this study is a multicentre, open label, non-comparative, two stage phase ii trial to assess the activity of zd1839 (iressa) in patients with malignant mesothelioma. patients will receive trial treatment as first-line therapy, administered continuously once daily until the completion of six 4-week cycles of treatment, disease progression, unacceptable toxicity or withdrawal of consent. patients continuing to show evidence of response, disease stabilization or clinical benefit from zd1839 may continue to receive therapy beyond completion of the trail.


Eligibility criteria:
inclusion criteria: * histologically-confirmed malignant mesothelioma (based on pleural biopsy); eligibility for first line therapy for malignant mesothelioma * uni or bi- dimensionally measurable disease * no prior radiotherapy within 3 weeks of enrolment into the trial * no significant comorbid disease exclusion criteria: * other malignancies, either co-existing or diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ * brian metastasis or leptomeningeal carcinomatosis * any unresolved chronic toxicity greater than ctc grade 2 from previous anticancer therapy * concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, or st. john's wort

Keywords: malignant mesothelioma iressa zd1839
discerning the impact of ctdna detection on patient decision making in early stage breast cancer: a conjoint analysis

Conditions: Triple Negative Breast Cancer

Summary: this study will examine how ctdna and additional prognostic genomic information in patients with early stage breast cancer might influences patient decision- making regarding systemic therapy options.

this study is an electronically delivered, one time cross sectional survey study. the investigators want to understand how patients with triple negative breast cancer at high risk for disease recurrence will prioritize additional benefit over toxicity when considering treatment options, and if their knowledge of ctdna positivity versus negativity will further shift this balance toward benefit.

Eligibility criteria:
inclusion criteria: * self- reported history of non-metastatic breast cancer * self- reported history of receiving chemotherapy for breast cancer * self- reported history of chemotherapy completed at least 6 months ago but no more than 10 years ago * able to complete an online survey * english speaking exclusion criteria: n/a

Keywords: breast cancer, ctdna
the partners scale-up project

Conditions: HIV-1-infection

Summary: an implementation project to scale-up delivery of antiretroviral-based hiv-1 prevention methods to kenyan hiv-1 serodiscordant couples in hiv-1 care centers. pre-exposure prophylaxis (prep) as a bridge to antiretroviral therapy (art) hiv-1 prevention strategy will be introduced into 24 public hiv-1 care centers in central and western kenya according to national guidelines using a stepped wedge design, stratified by region.

prep as a bridge to art strategy will be introduced into 24 kenyan public hiv-1 care centers according to national guidelines, in staged fashion, stratified by region (a stepped wedge design). monitoring and evaluation activities will identify implementation barriers and solutions, characterize costs, and provide best practices for further scale-up. a research component will establish prospective open cohorts of couples at each clinic (up to 200) to study how the program is effectively implemented. follow-up in the cohorts will be for up to 36 months at each care center and will evaluate impact, costs, and facilitators and barriers to implementation at patient, provider and health system levels.

Eligibility criteria:
inclusion criteria: * for hiv-1 uninfected members of the couple * age ≥18 * able and willing to provide consent for follow-up in the cohort * hiv-1 uninfected based on negative hiv-1 tests, per kenya national guidelines * not currently using prep for hiv-1 infected members of the couple * age ≥18 * able and willing to provide consent for follow-up in the cohort * hiv-1 infected based on positive hiv-1 tests, per kenya national guidelines * not currently using art for both members of the couple - meet criteria for initiating prep as per kenya national guidelines, including: * hiv-1 infected member not currently using art, on art \<6 months, or on art but not virally suppressed based on a viral load test done at the clinic as per kenya national guidelines or * trying to conceive for key delivery informants - able and willing to provide consent exclusion criteria: * otherwise not eligible based on the above inclusion criteria

Keywords: hiv-1 serodiscordant couples prep as bridge to art
effect of psychological interventions on maternal outcomes undergoing cesarean

Conditions: Perioperative Psychology

Summary: pregnancy induced psychosis is an essential factor that influencing maternal health postpartum. when gravidas, especially nulliparas, facing labor and delivery, they will undoubtedly encounter burden from their own and surrounding facts. maternal psychosis takes a large part of women's psychological disorders. no matter which way, either spontaneous or surgical, they would choose, many factors influence their psychological state. cesarean section poses higher risks for women than vaginal delivery. therefore, how to seek effective methods to alleviate parturients' psychological stress response possesses pivotal clinical implications. herein the investigators proposed that different linguistic interventions given pre-, intra- or post-operatively would produce different effect on maternal psychology and internal stress level.


Eligibility criteria:
inclusion criteria: * chinese gravidas * gestational age \>=36 wk * nulliparas * undergoing selective cesarean section exclusion criteria: * with recognition problem * used or using centrally acting drugs * with chronic pain * refusal participation * with existed psychiatric disorders * with history of psychological diseases * contraindications for neuraxial anesthesia

Keywords: linguistic stress response corticosteroid cesarean section anxiety depression maternal psychosis
primary anterior cruciate ligament repair with and without lateral extraarticular tenodesis

Conditions: Anterior Cruciate Ligament Tear

Summary: the investigators aimed to compare the clinical results of primary repairs and lateral extraarticular tenodesis applied with primary repairs in the treatment of proximal acl tears.

the investigators aimed to compare the clinical results of primary repairs and lateral extraarticular tenodesis applied with primary repairs in the treatment of proximal acl tears.the aim of this study was to determine the potential for improvement with the primary repair of acute acl tears with the proximal tear, which may be an important advance for improvements in proprioception and preservation of natural kinematics.

Eligibility criteria:
inclusion criteria: * patients who underwent surgery within the first 3 weeks after injury * between the ages of 21-40 years, * attended regular follow-up visits, * sherman type 1 proximal acl tear with relatively preserved synovial sheath * sufficient tissue length for re-stretching. exclusion criteria: * torn acl in the mid and distal region, * torn synovial sheath, * inability to undergo intrasubstance suturing, * poor tissue quality with retraction, * multiple ligament injuries and accompanying intra-knee pathologies (meniscal damage, chondral damage), * previous knee surgery, * rheumatologic diseases

Keywords: proximal anterior cruciate ligament tear primary repair lateral extraarticular tenodesis
egg intake and risk of type 2 diabetes

Conditions: Type 2 Diabetes; Heart Diseases

Summary: this is a longitudinal study that will collect demographic, anthropometric and dietary data to determine the relationships between meat and egg intake and the incidence of type 2 diabetes.

subjects of the adventist health study who are non-diabetic will provide demographic, anthropometric and dietary data at baseline. meat and egg intake will be assessed with a validated quantitative food frequency intake questionnaire. the relationship between meat and egg intake and the incidence of type 2 diabetes will be determined using multivariate-adjusted logistic regression.

Eligibility criteria:
inclusion criteria: * ahs 2 participants who filled out hospital history questionnaire version 3 or 5 age \> 30 years exclusion criteria: * subjects with missing values in dietary variables were excluded from the analytic sample, * missing gender * age \< 30 years * improbable questionnaire response patterns * extremes of bmi (less than 16 or greater than 60) * estimated energy intake (less than 500 or greater than 4,500 kcal/d) * existing cases of type 1 or type 2 diabetes at baseline * inconsistent reports of t2d between hhq version 3 and 5

Keywords: egg meat western diet type 2 diabetes adventist health study vegetarian cohort adventist
lateral postural inclination in parkinson's disease : involvement of the basal ganglia ?

Conditions: Parkinson Disease

Summary: the objective of this study is to assess the origins of lateral postural inclination presented by some parkinson disease's patients. several mechanisms could cause lateral postural inclination. available data allow to suggest three hypothesis: (troubles of tonus, perception of vertical perturbation, trouble of perception of corporal axis

inclusion criteria: * 30 to 75 years old patient * parkinson disease's diagnosed since 5 years * treated by deep brain stimulation * patient with at least 6 degree lateral deviation * without vestibular troubles nor peripheral sensorial trouble. exclusion criteria: * dementia (mattis \< 130 ou mms \<24), or severe depressive episode according to dsm iv-r criteria * camptocormia or incompatible anteflexion with the dispositive of measure device * pregnant woman, nursing mother

Eligibility criteria:
inclusion criteria: * 30 to 75 years old patient * parkinson disease's diagnosed since 5 years * treated by deep brain stimulation * patient with at least 6 degree lateral deviation * without vestibular troubles nor peripheral sensorial trouble. exclusion criteria: * dementia (mattis \< 130 ou mms \<24), or severe depressive episode according to dsm iv-r criteria * camptocormia or incompatible anteflexion with the dispositive of measure device * pregnant woman, nursing mother